Back to Results
First PageMeta Content
Oncogenes / Amines / Quinazolines / Organochlorides / Piperazines / Protein kinase inhibitor / C-Raf / KRAS / BRAF / Chemistry / Organic chemistry / Medicine


Document Date: 2010-02-26 05:11:36

Open Document

File Size: 1,30 MB

Share Result on Facebook

City

Orlando / /

Company

TopoTarget A/S / TenX Biopharma / Amgen / LEAD Therapeutics BioMarin Pharmaceutical / CML Cells BioMarin / Dako / SMARTANALYST INDIA PVT LTD / Pierre Fabre SA / Ascentage Pharma Group Corporation / mCRC Meets Primary Endpoint Poniard Pharmaceuticals / Spectrum Pharmaceuticals / TopoTarget Spectrum Pharmaceuticals / Dako Denmark / Keryx Biopharmaceuticals / BioMarin / Genmab TenX Biopharma / Ascentage Pharma / LEAD Therapeutics Mutant / mAb Abbott / Pfizer / Poniard / AstraZeneca / 3SBio / Business News (Cont'd) BioMarin / Primary Endpoint Poniard Pharmaceuticals / /

Continent

Europe / North America / /

Country

Canada / China / India / Mexico / United States / /

Currency

USD / /

Event

Business Partnership / FDA Phase / Product Issues / Funding / M&A / Security Buyback / /

IndustryTerm

cancer therapy / pharmaceutical sector / Cancer Therapeutics / therapies for cancers / decision-making process / tumor site / treatment of patients with T cell cancers / treatment for stage II and III colon cancer / treatment of cancer / manufacturing / oncology products / supplemental applications / cancer treatment / treatment of advanced colorectal cancer / pharmaceutical / treatment for advanced / metastatic colon cancer / treatment of cutaneous and peripheral T cell lymphoma / pharmaceutical and bio tech / chemical proteomics native target profile / chemical codes / /

MedicalCondition

advanced colorectal cancer / appropriate cancer / melanoma / T cell cancers / MSI-high tumors / Leukemia / tumor / gastrointestinal stromal tumor / H1299 lung cancer / cancer / tumors / NSCLC / human cancer / bone metastases / erlotinib-resistant tumors / diseases / spinal cord compression / EGFR-mutant lung cancers / Commercialize Cancer Therapeutics 3SBio / wild-type tumor / primary tumor / T cell lymphoma / PML-RARA leukemia / right-sided tumors / EGFR-mutant lung cancer / genetically defined cancers / metastasis / colon cancer / prostate and ovarian cancers / refractory Peripheral T-Cell Lymphoma / advanced non-small cell lung cancer / BRAF-mutant tumors / renal cell carcinoma / III colon cancer / mutant p53-expressing cancers / advanced / metastatic colon cancer / infections / cancers / advanced prostate cancer / disease / invasive and metastatic cancers / solid tumor / MSI-stable tumors / metastatic colorectal cancer / advanced cancer / EGFR-mutant cancers / advanced pancreatic neuroendocrine tumors / chronic myeloid leukemia / /

MedicalTreatment

surgery / radiation / cancer therapy / Chemotherapy / cancer therapeutics / drug therapies / /

MusicGroup

Superior / /

Organization

American Society of Clinical Oncology / FDA / European Union / Data Monitoring Committee / /

Person

Jerry McMahon / Senescence Abbott / Anuradha Dhingra / Gardiner F.H. Smith / Vinamrata Bhatia / Sarika Manchanda / Pierre Fabre / Meenu Grover / Ruth March / Shirish Kumar / /

Position

Chairman and CEO / CEO / Personalized Healthcare Leader / leader / /

Product

carboplatin / Herceptin / Rituxan / Zanolimumab / TYKERB / paclitaxel / Tasigna / Zometa / IRESSA / Belinostat / fluorouracil / Sutent / existing therapies / Picoplatin / ErbB2 / EU / PETACC-3 / KRX-0401 / /

ProvinceOrState

Florida / /

PublishedMedium

the Journal of Clinical Oncology / /

Technology

radiation / Proteomics / diagnostic tests / apoptosis / gene expression / Chemotherapy / treating cancer / alpha / antibodies / epigenomics / DNA synthesis / drug development / /

URL

www.smartoncology.com / /

SocialTag